IINN icon

Inspira Technologies Oxy

0.6691 USD
+0.0277
4.32%
At close Apr 2, 4:00 PM EDT
After hours
0.6200
-0.0491
7.34%
1 day
4.32%
5 days
-7.13%
1 month
-22.75%
3 months
-36.28%
6 months
-48.92%
Year to date
-36.28%
1 year
-64.41%
5 years
-85.91%
10 years
-85.91%
 

About: Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Employees: 37

0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

30% more funds holding

Funds holding: 10 [Q3] → 13 (+3) [Q4]

4% more capital invested

Capital invested by funds: $188K [Q3] → $196K (+$7.62K) [Q4]

0.29% more ownership

Funds ownership: 0.75% [Q3] → 1.04% (+0.29%) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

Research analyst outlook

We haven’t received any recent analyst ratings for IINN.

Financial journalist opinion

Based on 9 articles about IINN published over the past 30 days

Neutral
PRNewsWire
1 week ago
Inspira Technologies Announces Successful Installation of INSPIRA ART100 Systems in Premier U.S. Hospital
Inspira's innovative FDA-cleared INSPIRA™ ART100 system was successfully deployed at premier U.S. hospital, with systems in place for clinical use RA'ANANA, Israel , March 25, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has successfully completed the installation, training program and operational readiness for its INSPIRA ART100 system for cardiopulmonary bypass procedures at one of New York's premier hospitals.
Inspira Technologies Announces Successful Installation of INSPIRA ART100 Systems in Premier U.S. Hospital
Neutral
Business Wire
1 week ago
Market Alert: Inspira Technologies' Respiratory Tech Could Transform $19B Ventilator Market Amid Major Wave of Multi Billion Dollar Medtech Acquisitions
NEW YORK--(BUSINESS WIRE)--Market News Alerts Reports: Inspira Technologies (NASDAQ: IINN)* is reported beginning deployment of its FDA-cleared INSPIRA ART100 system at a leading New York cardiothoracic program ranked among the top 15% nationally, marking a significant commercialization milestone in a sector experiencing unprecedented M&A activity. The medtech industry saw multiple billion-dollar acquisitions in 2024, including Johnson & Johnson's $13.1 billion acquisition of Shockwave.
Market Alert: Inspira Technologies' Respiratory Tech Could Transform $19B Ventilator Market Amid Major Wave of Multi Billion Dollar Medtech Acquisitions
Neutral
PRNewsWire
2 weeks ago
Inspira Technologies' Innovative Life-Support System to be Showcased at AmSECT 63rd International Conference 2025 in San Diego
Leading perfusion professionals to experience Inspira's FDA-cleared cardiopulmonary bypass INSPIRA™ ART100 technology at premier industry event RA'ANANA, Israel , March 19, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira," "Inspira Technologies" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that its U.S. Food and Drug Administration-cleared life-support system, the INSPIRA™ ART100, will be showcased at the American Society of Extracorporeal Technology (AmSECT) 63rd International Conference, taking place March 19-23, 2025, at the Loews Coronado Bay Resort in San Diego, California, by their distributor Glo-Med Networks Inc ("Glo-Med").
Inspira Technologies' Innovative Life-Support System to be Showcased at AmSECT 63rd International Conference 2025 in San Diego
Neutral
Business Wire
2 weeks ago
PESG Report: Inspira Technologies' AI-Powered Respiratory System Could Revolutionize Care for 20 Million Annual ICU Patients in Combined $25+ Billion Market
NEW YORK--(BUSINESS WIRE)---- $IINN #biotech--PESG Research releases an update following Inspira Technologies' (NASDAQ: IINN)* recent strategic developments and clinical achievements: Inspira has emerged as a potential disruptive force in respiratory care with its integrated technology approach. The company's recent clinical studies demonstrating 96% accuracy for its AI-powered HYLA blood sensor represent a significant technological validation as it targets multiple high-value healthcare segments. Inspira's integ.
PESG Report: Inspira Technologies' AI-Powered Respiratory System Could Revolutionize Care for 20 Million Annual ICU Patients in Combined $25+ Billion Market
Neutral
PRNewsWire
2 weeks ago
Inspira Technologies Releases CEO Update: Major Milestones Signal Next-Level Respiratory Care
Letter from the CEO / March 14, 2025 RA'ANANA, Israel , March 14, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. ("Inspira," "Inspira Technologies" or the "Company") (Nasdaq: IINN), a pioneering force in the evolution of respiratory support and real-time blood-monitoring technologies, is pleased to share this update to shareholders from its Chief Executive Officer, Director, and Co-founder, Mr.
Inspira Technologies Releases CEO Update: Major Milestones Signal Next-Level Respiratory Care
Neutral
PRNewsWire
2 weeks ago
Inspira Technologies Receives Nasdaq Notification Regarding Minimum Bid Requirement
RA'ANANA, Israel , March 13, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that on March 10, 2025, the Company received a written notice (the "Notice") from the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the Company's closing bid price for its ordinary shares, or Ordinary Shares, was below $1.00 per share for the last 30 consecutive business days.
Inspira Technologies Receives Nasdaq Notification Regarding Minimum Bid Requirement
Neutral
PRNewsWire
3 weeks ago
Inspira Technologies Reports Full Year 2024 Financial Results and Provides Business Updates
Significant progress in HYLA blood sensor and INSPIRA ART core technologies RA'ANANA, Israel , March 11, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the full year ended December 31, 2024, and provided a corporate update.
Inspira Technologies Reports Full Year 2024 Financial Results and Provides Business Updates
Neutral
Business Wire
4 weeks ago
PESG Report: Inspira Technologies Breaks new Ground with Positive Clinical Data for AI-Powered Blood Sensor Exceeding Expectations
NEW YORK--(BUSINESS WIRE)---- $IINN #biotech--PESG Research releases an update following groundbreaking clinical evaluation results: Inspira Technologies* (NASDAQ: IINN) has reported exceptional clinical study outcomes for its HYLA blood sensor, with 96% accuracy achieved in a key parameter compared to traditional blood analyzers. This milestone achievement validates the company's AI-powered continuous blood monitoring technology and accelerates its path toward commercial deployment in multiple healthcare setting.
PESG Report: Inspira Technologies Breaks new Ground with Positive Clinical Data for AI-Powered Blood Sensor Exceeding Expectations
Neutral
PRNewsWire
4 weeks ago
Inspira Technologies Announces Positive Results from Clinical Study of HYLA Blood Sensor, Achieving 96% Accuracy
Inspira's AI-powered continuous blood monitoring technology demonstrated a high degree of accuracy in a key parameter, targeting multiple multi-billion-dollar market segments; Company plans to advance with ongoing clinical study following this success; FDA submission planned for H2 2025 RA'ANANA, Israel , March 4, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced positive results from the clinical study of its AI-powered HYLA™ blood sensor.
Inspira Technologies Announces Positive Results from Clinical Study of HYLA Blood Sensor, Achieving 96% Accuracy
Neutral
PRNewsWire
1 month ago
Inspira Achieves Positive Results of Above 95% For Preventing Bloodstream Infections
The ex-vivo testing demonstrated significant bacterial reduction for the innovative IV dressing technology aimed at preventing bloodstream infections in critical patients RA'ANANA, Israel , Feb. 11, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in breakthrough life-support technology, today announced positive initial results from its previously reported collaboration with Ennocure MedTech Ltd.
Inspira Achieves Positive Results of Above 95% For Preventing Bloodstream Infections
Charts implemented using Lightweight Charts™